Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations

Fabrizio D'Ascenzo, Umberto Barbero, Mohamed Abdirashid, Daniela Trabattoni, Giacomo Boccuzzi, Nicola Ryan, Giorgio Quadri, Davide Capodanno, Giuseppe Venuti, Saverio Muscoli, Francesco Tomassini, Michele Autelli, Andrea Montabone, Wojciech Wojakowski, Andrea Rognoni, Diego Gallo, Radoslaw Parma, Leonardo De Luca, Filippo Figini, Satoru MitomoAntonio Montefusco, Alessio Mattesini, Wojciech Wańha, Marcin Protasiewicz, Grzegorz Smolka, Zenon Huczek, Cristina Rolfo, Bernardo Cortese, Alaide Chieffo, Wiktor Kuliczowki, Ivan Nuñez-Gil, Umberto Morbiducci, Fabrizio Ugo, Giorgio Marengo, Mario Iannaccone, Enrico Cerrato, Carlo di Mario, Claudio Moretti, Maurizio D'Amico, Ferdinando Varbella, Thomas F. Lüscher, Imad Sheiban, Javier Escaned, Francesco Romeo, Mauro Rinaldi, Gaetano Maria De Ferrari, Gerard Helft

Research output: Contribution to journalArticle

Abstract

Incidence and predictors of adverse events after dual antiplatelet therapy (DAPT) cessation in patients treated with thin stents (<100 microns) in unprotected left main (ULM) or coronary bifurcation remain undefined. All consecutive patients presenting with a critical lesion of an ULM or involving a main coronary bifurcation who were treated with very thin strut stents were included. MACE (a composite end point of cardiovascular death, myocardial infarction [MI], target lesion revascularization [TLR], and stent thrombosis [ST]) was the primary endpoint, whereas target vessel revascularization (TVR) was the secondary endpoint, with particular attention to type and occurrence of ST and occurrence of ST, CV death, and MI during DAPT or after DAPT discontinuation. All analyses were performed according to length of DAPT dividing the patients in 3 groups: Short DAPT (3-months), intermediate DAPT (3 to 12 months), and long DAPT (12-months). A total of 117 patients were discharged with an indication for DAPT ≤3 months (median 1: 1 to 2.5), 200 for DAPT between 3 and 12 months (median 8: 7 to 10), and 1,958 with 12 months DAPT. After 12.8 months (8 to 20), MACE was significantly higher in the 3-month group compared with 3 to 12 and 12-month groups (9.4% vs 4.0% vs 7.2%, p ≤0.001), mainly driven by MI (4.4% vs 1.5% vs 3%, p ≤0.001) and overall ST (4.3% vs 1.5% vs 1.8%, p ≤0.001). Independent predictors of MACE were low GFR and a 2 stent strategy. Independent predictors of ST were DAPT duration <3 months and the use of a 2-stent strategy. In conclusion, even stents with very thin strut when implanted in real-life ULM or coronary bifurcation patients discharged with short DAPT have a relevant risk of ST, which remains high although not significant after DAPT cessation.

Original languageEnglish
Pages (from-to)491-499
Number of pages9
JournalAmerican Journal of Cardiology
Volume125
Issue number4
DOIs
Publication statusPublished - Feb 15 2020

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations'. Together they form a unique fingerprint.

  • Cite this

    D'Ascenzo, F., Barbero, U., Abdirashid, M., Trabattoni, D., Boccuzzi, G., Ryan, N., Quadri, G., Capodanno, D., Venuti, G., Muscoli, S., Tomassini, F., Autelli, M., Montabone, A., Wojakowski, W., Rognoni, A., Gallo, D., Parma, R., De Luca, L., Figini, F., ... Helft, G. (2020). Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 125(4), 491-499. https://doi.org/10.1016/j.amjcard.2019.10.058